Alteogen acquires U.S. formulation patent of biosimilar referencing ‘Eylea’
Alteogen officially announced on the 30th that the company acquired a U.S. patent of a stable liquid formulation of fusion protein with IgG Fc domain on 27 April.
According to the company, the patent, formulation technology of a biosimilar referencing Eylea, a macular degeneration therapy, is a ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
